Featured Speakers

Nadia Lovell

U.S. Equity Strategist
J.P. Morgan Global Wealth Management

Nadia is a U.S. Equity Strategist for J.P. Morgan Global Wealth Management. As part of the Global Equity team, Nadia helps develop the Private Bank’s U.S. equity views and identifies and markets stock-specific and thematic investment opportunities across U.S. equities. Before joining the Private Bank in 2014, Nadia spent 5 years in J.P. Morgan Equity Research, as a member of the Institutional Investor magazine ranked Media equity research team, where she published research and provided investment advice on over 20 companies.

Prior to that, she was an investment product specialist, primarily focused on fixed-income mutual funds, at American Funds of The Capital Group Companies.

Nadia received a B.A. in Math and Physics from Smith College and an M.B.A. from NYU Stern School of Business.  She is a Board member of Hunts Point Alliance for Children.

Eric Freedgood, CPA, CFA

Executive Vice President,

Chief Innovation Officer,

Senior Portfolio Manager

Pinnacle Associates, LTD

Eric began his professional career in 2003 after graduating with honors from Binghamton University. Upon graduating, he joined Ernst and Young (EY) where he audited and valued complex derivative instruments for large financial institutions, banks and funds. It was during this time he obtained his CPA license which

he still holds today. After his time at EY he joined Pinnacle Associates, Ltd- a Registered Investment Advisor in 2006 as an associate portfolio manager. In 2009 Eric obtained his Chartered Financial Analyst designation which he currently maintains. Over the years at Pinnacle, Eric has introduced many new portfolio strategies to clients that address current market and client needs and circumstances. Eric has focused his efforts on helping high net worth clients as well as small and medium sized institutions achieve their growth, income and risk-defined goals. Eric has always focused his clients’ success on what he refers to as the “two “C’s” of customization and communication. In 2011, Eric was asked to be a partner in the firm, which he gladly accepted. In 2020, given many of the new initiatives brought to Pinnacle over the years, Eric was asked to serve as the firm’s Chief Innovation Officer- a new roll he is very excited about to ensure discovery and implementation of new strategies, tools and ideas in the investment program.  Eric is an avid reader, runner, and hiker and he recently has taken up gravel biking. His main joy, however is spending time with his wife Rachael and their two young sons.

Michele Cleary, Ph.D
Chief Executive Officer
The Mark Foundation for Cancer Research

Michele Cleary joined The Mark Foundation for Cancer Research as Chief Executive Officer in January 2017. Since that time, she has recruited a high performance scientific and administrative team and built a global research portfolio of over $100 million in grants and early-stage investments. Prior to her role at The Mark Foundation, Michele was Vice President at Bristol-Myers Squibb (BMS). At BMS, she led early clinical and translational research teams using cutting-edge

technologies to accelerate drug discovery and development for cancer and other diseases. Before joining BMS, Michele held several senior level positions at Merck & Co., Inc. overseeing the development and application of innovative platforms aimed at understanding molecular mechanisms of cancer, identifying new therapeutic approaches for multiple diseases, and functionally validating novel drug targets identified through human genetics. At Merck, her research teams also conducted pioneering work using genetic screens for new drug targets and biomarkers in cancer.

Michele is co-author of more than 50 primary research papers and co-inventor on multiple patents for new technologies with direct application to drug development. She received a PhD in Molecular Microbiology and Genetics from Stony Brook University and completed graduate research at Cold Spring Harbor Laboratory followed by postdoctoral training at Princeton University. 

Wendy Yeh, MD
Senior Vice President, Clinical Research

Vir Biotechnology

Dr. Yeh has served as the Senior Vice President of Clinical Research at Vir since August 2020.  Prior to that, she was at Principia Biopharma in South San Francisco leading the clinical development of BTK inhibitors in multiple immune-mediated diseases.  From 2012-2019, Dr. Yeh was at Merck Research Laboratories in Boston where she made significant contributions to the Merck Infectious Disease portfolio, such as the development of multiple hepatitis C virus

compounds including the approval of a HCV combination, as well as the life cycle management of the CMV antiviral program.

After receiving her undergraduate degree in Biological Sciences from Stanford University, Dr. Yeh earned her M.D. from University of Washington in 2000 and completed her Internal Medicine training at the Brigham and Women’s Hospital and her Infectious Disease fellowship at Massachusetts General Hospital/Brigham and Women’s Hospital in Boston.  Prior to joining industry, Wendy previously held the position of Assistant Professor in Medicine at Harvard Medical School. 

John Maraganore, Ph.D

Chief Executive Officer
Alnylam Pharmaceuticals

Since 2002, Dr. John Maraganore has served as the CEO and a Director of Alnylam. Prior to Alnylam, Dr. Maraganore served as an officer and a member of the management team for Millennium Pharmaceuticals, Inc. As Senior Vice President, Strategic Product Development for Millennium, he was responsible for the company’s product franchises in oncology, and cardiovascular, inflammatory, and metabolic diseases. He was previously Vice President, Strategic

Planning and M&A and, prior to that, he was General Manager of Millennium BioTherapeutics, Inc., a former subsidiary of Millennium. Before Millennium he served as Director of Molecular Biology and Director of Market and Business Development at Biogen, Inc. At Biogen, Dr. Maraganore invented and led the discovery and development of ANGIOMAX® (bivalirudin) for injection, formerly HIRULOGTM and currently marketed by The Medicines Company. Prior to Biogen, Dr. Maraganore was a scientist at ZymoGenetics, Inc., and the Upjohn Company.


Dr. Maraganore received his Master of Science and Ph.D. in biochemistry and molecular biology at the University of Chicago. He is a member of the Board for Agios Pharmaceuticals and Biotechnology Industry Organization (BIO) Board and is a member of the BIO Executive Committee.